US Bancorp’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

US Bancorp’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$16	–	4220
2022 Q4	$16	Hold	1	–	–	﹤0.01%	4120
2022 Q3	$0	Hold	1	–	–	﹤0.01%	4259
2022 Q2	$0	Hold	1	–	–	﹤0.01%	4281
2022 Q1	$0	Hold	1	–	–	﹤0.01%	4242
2021 Q4	$0	Hold	1	–	–	﹤0.01%	4257
2021 Q3	$0	Hold	1	–	–	﹤0.01%	4197
2021 Q2	$0	Hold	1	–	–	﹤0.01%	4095
2021 Q1	$0	Sell	1 -2	-67%	-$203	﹤0.01%	3985
2020 Q4	$0	Hold	3	–	–	﹤0.01%	3910
2020 Q3	$0	Sell	3 -48	-94%	-$5.59K	﹤0.01%	3881
2020 Q2	$5K	Sell	51 -575	-92%	-$31.7K	﹤0.01%	3345
2020 Q1	$18K	Buy	626 +243	+63%	+$9.45K	﹤0.01%	2811
2019 Q4	$16K	Buy	+383	New	+$8.39K	﹤0.01%	2973

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

US Bancorp's VBIV Position: Q1 2023 in Review

US Bancorp sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 1 share — an estimated $16 sold.

US Bancorp first reported a position in VBIV in Q4 2019 and held it in 13 quarters. The position peaked at $18K in Q1 2020. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

US Bancorp reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
US Bancorp sold 1 VBI Vaccines, Inc. New Common Stock (Canada) share in Q1 2023, an estimated $16.
US Bancorp first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2019 and held it in 13 quarters.
US Bancorp's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $18K in Q1 2020.
95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on US Bancorp's 13F filing for Q1 2023, filed 9 May 2023.